USANA Health Sciences Inc.'s director, Gilbert A. Fuller, executed a transaction involving his common stock recently. On May 22, 2026, Mr. Fuller disposed of 1,057 shares of the company's common stock. The total value realized from this sale was $19,728.
Details concerning the disposition show that the shares were sold at a weighted average price of $18.6648 per share. These transactions took place within an observed price spectrum ranging from $18.62 to $18.775 per share, inclusive of both ends of the range.
Following this reported sale, Mr. Fuller's direct ownership holding in USANA Health Sciences common stock was reduced to zero shares. This insider selling activity is notable given the broader performance trends observed for USANA stock.
Market Context and Valuation Analysis
The timing of this insider disposal occurs as USANA stock has experienced a decline of 36% over the past year. Currently, the stock is trading 52% below its 52-week high, which was recorded at $38.32.
Despite the observed downward pressure on share price, analysis provided by InvestingPro suggests that the equity may be undervalued at its current market levels. The platform's Fair Value indicator points toward potential significant upside for the stock. Furthermore, an InvestingPro tip highlights a key balance sheet characteristic: the company maintains more cash than debt.
Recent Corporate Performance and Governance
In separate corporate developments, USANA Health Sciences reported financial results for its first quarter of 2026 that were marked by impressive performance. The company exceeded market expectations in both revenue generation and overall earnings. Specifically, USANA achieved earnings per share (EPS) of $0.61. This figure substantially surpassed the forecasted EPS of $0.40, representing a positive surprise margin of 52.5%.
Revenue figures also demonstrated strength, reaching $250 million. This amount was higher than the expected revenue of $240.95 million. In addition to these financial milestones, USANA Health Sciences conducted its annual shareholder meeting. At this meeting, representation was strong, with approximately 89% of issued and outstanding shares being represented.
During the shareholder session, shareholders elected eight directors for the upcoming year's board. Kevin G. Guest and Xia Ding were among those individuals named in the election. For each nominee, a substantial number of votes were recorded in favor, alongside documented broker non-votes. These recent operational and governance activities reflect both the company’s performance trajectory and its internal corporate structure.
Key Observations
- Despite strong quarterly earnings, the stock has declined 36% over the past year and trades 52% below its 52-week high.
- The director's sale of shares (1,057 shares valued at $19,728) occurred while the company is facing significant price pressure.